Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

The requested reference [4d9455c721fd9cb6486327aec4786cc3c3892a15] no longer exists in our database. It has been replaced by the current reference: [859c1b7af05780fbed261081ba652f21be95df54]

Authors Hualan Biological Engineering, Inc. -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
Links ClinicalTrials.gov
Influenza vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml) of Hualan Biological Bacterin Co., Ltd (The subsidiary of Hualan Biological Engineering INC.) is applicable to the influenza immunity of age 3 and older population. Phase III clinical study was conducted in Jintan City, Jiangsu Province in May, 2006. Trial results showed that this vaccine had good safety and immunogenicity. Hualan Bio Influenza Vaccine obtained its production approval(China Drug Approval No.: S20083016) for marketing on April 3rd, 2008. In order to monitor and evaluate the safety and protective effect against influenza administered on age 3 and older population, therefore we conduct the phase IV clinical trial of the licensed Influenza Vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml).
Epistemonikos ID: 3eebd0610038a1312e3e12fe39782e6f038832d0
First added on: May 10, 2024